x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Bio Report

Levine Media Group

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

science life sciences

All Episodes

38:47

Reprogramming T Cells to Cross the Brain’s Border

The Bio Report ·

2026/02/04

One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has developed platform technology that harnesses a patient’s own T cells to transport bispecific therapeutic payloads across the blood-brain barrier and into other targeted tissue with an initial focus on treating glioblastoma. We spoke to Michael Roberts, co-founder and CEO of Adaptin Bio, about the unmet need in glioblastoma, the limitations of current blood-brain

en

46:31

A Billion Dollar Bet on AI-First Drug Development

The Bio Report ·

2026/01/28

Despite the emergence of new modalities and drug development technologies, the cost and time to produce new therapies has changed little, and failure rates remain high. Xaira aims to change that with a systematic, AI‑driven approach that tackles three pervasive bottlenecks—choosing the right targets, designing the right molecules, and matching the right patients—by running as much work as possible in silico and using high‑dimensional causal datasets to train “virtual cell” foundation models. The

en

37:46

Finding New Targets on the Surface of Misfolded Proteins

The Bio Report ·

2026/01/21

Finding New Targets on the Surface of MisfoldedOne of the biggest hurdles in drug development is targeting proteins found in both healthy and diseased cells without triggering toxic side effects. In cancer, this challenge often translates into narrow therapeutic windows, collateral damage to normal tissues, and forced dose reductions that limit efficacy. The result is a crowded field where many companies chase the same well-known targets, leaving vast patient populations without effective options

en

30:20

Targeting Tumors from the Inside Out

The Bio Report ·

2026/01/14

Systemic chemotherapy remains the foundation of cancer treatment, but its widespread toxicity too often cuts short potential therapeutic benefits. Nanology is developing a new approach—localized cancer therapy that keeps the drug where it’s needed most. We spoke to Marc Iacobucci, managing director of Nanology about the company’s precision particle engineering platform, how it transforms existing oncology drugs into microparticles optimized for intratumoral delivery; and how this enables sustained,

en

29:20

An Effort to Detect and Treat Alzheimer’s at Its...

The Bio Report ·

2026/01/07

One of the challenges in treating the neurodegenerative condition Alzheimer’s disease is intervening early enough in the course of illness to provide meaningful benefit. AltPep is developing therapeutics with companion diagnostics that target toxic α-sheet–containing oligomers, which are thought to form very early in the disease and act as molecular triggers of downstream amyloid pathology. These structures are believed to represent some of the earliest detectable stages of Alzheimer’s and to

en

38:15

The Year in Biotech and What’s Ahead for 2026

The Bio Report ·

2025/12/31

Biotech stocks staged a dramatic turnaround in 2025, with the XBI well outpacing the S&P 500 despite concerns over leadership changes at the U.S. Food and Drug Administration, the Trump administration’s efforts to put constraints on drug pricing, and its broader cuts to health and science agencies. A pick-up in deal-making, along with falling interest rates, helped buoy the sector with growing anticipation for continued improvement in 2026. We sat down with Adam Feuerstein, senior biotech writer

en

25:47

Developing an Alternative to Opioids for...

The Bio Report ·

2025/12/24

The approach to post-surgical pain relief has relied on short-duration treatments and notably opioids. That’s led to the associated risks of dependence and abuse, prolonged hospitalizations, and slower recoveries. Allay Therapeutics is developing an alternative to opioids to treat post-surgical pain with an initial focus on knee replacement surgeries. Allay’s guitar pick-sized polymer is implanted during surgical procedures and it releases the analgesic bupivacaine as it dissolves over 30 days. We

en

22:19

Leveraging the Power of Vocal Biomarkers

The Bio Report ·

2025/12/17

Physicians can learn a lot from talking to patients, and not just from the words they say, but from millions of data points from acoustic features of their speech, such as pitch, vocal cord vibration patterns, and micro-instabilities in the voice. Canary Speech has developed an AI-based diagnostic listening tool that can detect neurological and psychiatric conditions from physiological signals in the voice. We spoke to Kang Hsu, chief medical officer of Canary Speech, about how its diagnostic tool

en

37:09

Determining the Cause and Severity of Sepsis with a...

The Bio Report ·

2025/12/10

Sepsis remains one of medicine’s most intractable and costly problems, arising when an infection triggers a runaway immune response that damages organs long after a pathogen is controlled. It accounts for an estimated $53 billion in Medicare spending alone, yet more than a hundred drug trials have failed to yield a single approved drug that directly treats the underlying immune dysfunction. Inflammatix, which grew out of work at Stanford University, has developed a point-of-care blood test to

en

32:21

Separating Signal from Noise in Regenerative Therapies

The Bio Report ·

2025/12/03

Rion is developing platelet-derived exosome therapeutics as off-the-shelf, room-temperature-stable alternatives to traditional cell therapies. The company’s lead program is advancing toward phase 3 trials in diabetic foot ulcers, and it is building a broader pipeline across musculoskeletal, cardiovascular, pulmonary, dermatologic, and women’s health indications. The company is built on stem cell research conducted at the Mayo Clinic that showed that regenerative benefits from treatments stemmed from

en

45:49

Rewriting Drug Discovery with an AI-Multi-Omics Approach

The Bio Report ·

2025/11/26

The genomics revolution promised to unravel diseases and lead to treatments that addressed their root causes. In reality, says Mo Jain, your zip code remains a better predictor for how healthy you will be over the course of your life than your genetic code does. That’s because, except for monogenic diseases, etiology tends to be far more complex than the identification of a single gene. Sapient Bio company is using its AI-driven, multi-omics platform to advance the discovery and development of

en

36:24

Overcoming Chemoresistance and Activating the Immune...

The Bio Report ·

2025/11/19

The enzyme GSK3β, in healthy cells, is involved in glucose metabolism. In cancer cells, though, it serves as a master regulator of tumor growth, progression, and cell survival. While GSK3β has long been an attractive target in cancer therapy, it has been difficult to inhibit due to the poor pharmaceutical characteristics and adverse effects of therapeutic candidates. Actuate Therapeutics’ experimental therapy elraglusib has shown early promise. Results suggest it not only suppresses tumor growth but

en

21:26

A Hub-and-Spoke Ophthalmology Company with an Eye for...

The Bio Report ·

2025/11/12

Hub-and-spoke business models—the use of a central core of business functions with pipeline assets spun out into subsidiary companies—have gained traction for the benefits they can provide in terms of capital efficiency, diversification of risks, and improved access to capital. Eyexora is applying that business model to accelerate the development of therapies for ophthalmic indications. We spoke to Theresa Heah, CEO of Eyexora, about why the hub-and-spoke model is well-suited for the development of

en

55:46

An AI Collaborative that Welcomes All into the Fold

The Bio Report ·

2025/11/05

OpenFold, an open-source, collaborative initiative founded in 2022 to address the challenges of protein structure prediction and design using artificial intelligence, emerged as a response to the restricted commercial access to DeepMind’s AlphaFold platform. Leveraging public datasets and using a pre-competitive consortium model, OpenFold seeks to democratize cutting-edge protein engineering tools for both industry and academia. We spoke to Brian Weitzner, director of computational and structural

en

42:46

Hitting the Reset Button on Cellular Aging

The Bio Report ·

2025/10/29

Transcription factors control the genetic programs that maintain cellular balance, but while they have been seen as compelling targets for aging-related disease, they have long been considered “undruggable.” Junevity’s RESET platform leverages large-scale human omics data and AI models to pinpoint key transcriptional drivers of disease and to design siRNA therapies that restore healthy gene expression. We spoke to John Hoekman, co-founder and CEO of Junevity, about the role of transcription factors

en

29:58

Changing the Ovarian Cancer Treatment Landscape with...

The Bio Report ·

2025/10/22

Ovarian cancer remains one of the deadliest cancers affecting women, and it is expected to claim nearly 13,000 lives in the United States in 2025. Despite progress in survival rates, nearly 80 percent of patients are still diagnosed at advanced stages, when the disease has already spread and is difficult to treat. Imunon’s experimental DNA-mediated immunotherapy is designed to deliver interleukin-12 directly into the tumor. A phase 2 study demonstrated that the experimental therapy, when combined

en

32:39

Why the United States Must Fall in Love with...

The Bio Report ·

2025/10/15

China’s emergence as a biotech superpower may have appeared to happen suddenly, but it reflected a long-term vision and policies over many years that enabled its success. As biotechnology transforms not only medicine but also industries such as food, fuel, and materials, the competition between China and the United States to shape the future bioeconomy is intensifying. We spoke to Drew Endy, associate professor of bioengineering and senior fellow of the Hoover Institution at Stanford University,

en

39:48

Transforming Drug Discovery and Disease Research—One...

The Bio Report ·

2025/10/08

The ARC Virtual Cell Atlas uses high-throughput single-cell genomics, artificial intelligence, and open science to understand the complexities of cellular behavior. Developed through a partnership between the ARC Institute, 10x Genomics, and Ultima Genomics, the public domain resource integrates data from hundreds of millions of cells. By curating and harmonizing vast amounts of single-cell measurements, the Atlas paves the way for virtual cell simulations that can predict how cells respond to

en

24:30

Scratching the Surface with a Novel Approach to...

The Bio Report ·

2025/10/01

Bronchopulmonary dysplasia is a condition that affects preterm infants, especially those born with underdeveloped lungs who require prolonged oxygen therapy or mechanical ventilation to help them breathe after birth. It is characterized by damage and abnormal development of the lung tissue and airways, often resulting from life-saving interventions necessary for babies born very prematurely. Airway Therapeutics is developing a new class of biologics for respiratory and inflammatory diseases,

en

29:37

A Dual Action Approach to Treating MASH

The Bio Report ·

2025/09/24

MASH, a chronic and progressive form of fatty liver disease that until recently was known as NASH, affects millions of people in the United States, and its incidence continues to rise. In fact, MASH is now among the leading causes of liver transplantation in the United States. 89bio is developing an experimental therapy to target multiple disease mechanisms of the condition. We spoke to Rohan Palekar, CEO of 89bio, about what’s driving the prevalence of MASH, the limits of existing medicines, and

en

305 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter